Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide

Annals of Oncology

Volumn 16, Issue 6, 2005, Pages 942-949

  Brada, Michael ^a,b   Ashley, S ^b   Dowe, A ^b   Gonsalves, A ^b   Huchet, A ^b   Pesce, G ^b,f   Reni, M ^d   Saran, F ^b   Wharram, B ^b   Wilkins, M ^e   Wilkins, P ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^f OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Malignant glioma; New agents; Temozolomide

Indexed keywords

ANTIEMETIC AGENT; NEW DRUG; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENERAL CONDITION DETERIORATION; GLIOBLASTOMA; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; INFECTION; ITALY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR BIOPSY; UNITED KINGDOM;

EID: 21344454458     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi183     Document Type: Article

References (35)

1. Rampling R. Chemotherapy. In Davies E, Hopkins A (eds): Improvement care for patients with malignant cerebral glioma. London: Royal College of Physicans 1997.
2. Wilson CB, Gutin P, Boldrey EB et al. Single-agent chemotherapy of brain tumors. A five-year review. Arch Neurol 1976; 33: 739-744.
3. Fine HA, Dear KB, Loeffler JS et al. Meta analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-2597.
4. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta- analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
5. Thomas D, Brada M, Stenning S, Partyobot MBTW. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001; 19: 509-518.
6. Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17: 1516-1525.
7. Yamamoto M, Oshiro S, Tsugu H et al. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha. Anticancer Res 2002; 22: 2447-2453.
8. Gregor A, Lind M, Newman H et al. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group. J Neurooncol 1999; 44: 137-145.
9. Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2001; 54: 31-38.
10. Short SC, Traish D, Dowe A et al. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 2001; 51: 41-45.
11. Brada M. NICE verdict on Temozolomide: where next? Br J Cancer 2002; 86: 499-500.
12. Brada M, Sharpe G. Chemotherapy of high grade gliomas: beginning of a new era or the end of the old? [editorial]. Eur J Cancer 1996; 32a: 2193-2194.
13. Brada M, Yung WK. Clinical trial end points in malignant glioma: need for effective trial design strategy. Semin Oncol 2000; 27 (Suppl 6): 11-19.
14. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
15. Brada M, Hoang-Xuan K, Rampling R et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12: 259-266.
16. Grossman SA, Wharam M, Sheidler V et al. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 1997; 15: 2596-2603.
17. Grossman SA. Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas. Semin Oncol 2003; 30 (Suppl 19): 19-22.
18. O'Reilly SM, Newlands ES, Glaser MG et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993; 7: 940-942.
19. Bower M, Newlands ES, Bleehen NM et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997; 40: 484-488.
20. Stupp R, Dietrich PY, Ostermann Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382.
21. Gilbert MR, Friedman HS, Kuttesch JF et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 2002; 4: 261-267.
22. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-458.
23. Peto R, Pike MC, Armitage P et al. Randomised clinical trials requires prolonged observation on each patient: Analysis and examples. Br J Cancer 1977; 35: 1-39.
24. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187-202.
25. Brada M, Stenning S. Radiotherapy for Malignant Gliomas in the Elderly. Semin Oncol 2003; 30 (Suppl 19): 63-67.
26. Fetell MR, Grossman SA, Fisher JD et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997; 15: 3121-3128.
27. Frenay M, Lebrun C, Lonjon M et al. Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. Eur J Cancer 2000; 36: 1026-1031.
28. Gilbert M, O'Neill A, Grossman S et al. A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Cooperative Oncology Group study (E2393). J Neurooncol 2000; 47: 145-152.
29. Gruber ML, Glass J, Choudhri H, Nirenberg A. Carboplatin chemotherapy before irradiation in newly diagnosed glioblastoma multiforme. Am J Clin Oncol 1998; 21: 338-340.
30. Jeremic B, Shibamoto Y, Grujicic D et al. Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study. Radiother Oncol 1999; 51: 27-33.
31. Lassen U, Kristjansen PE, Wagner A et al. Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neurooncol 1999; 43: 161-166.
32. Vinolas N, Gil M, Verger E et al. Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anticancer Drugs 2002; 13: 163-167.
33. Watne K, Nome O, Hager B, Hirschberg H. Pre-radiation chemotherapy in glioma patients with poor prognostic factors. J Neurooncol 1992; 13: 261-264.
34. Wick W, Hermisson M, Kortmann RD et al. Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study. J Neurooncol 2002; 59: 151-155.
35. Grossman SA, O'Neill A, Grunnet M et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003; 21: 1485-1491.